Carvykti

FDA Advisers Approve Carvykti and Abecma for Earlier Treatment Options

by

Washington, D.C. – An FDA advisory panel has recommended the approval of two groundbreaking cancer treatments, Carvykti and Abecma, for use in earlier stages of the disease. This decision comes despite initial concerns about potential risks associated with the treatments. Carvykti, developed by J&J and Legend, and Abecma, developed by BMS, have shown promising results … Read more

JNJ and LEGN Biotech Face FDA Scrutiny Over Carvykti Supplemental License Application

by

Washington, D.C. — The FDA’s Oncologic Drugs Advisory Committee is set to convene on Friday to deliberate on Johnson & Johnson and Legend Biotech Corporation’s supplemental biologics license application for Carvykti. This drug is intended for patients with relapsed or refractory multiple myeloma who have undergone previous lines of therapy. The panel will specifically analyze … Read more